Recurrent thrombotic events (arterial or venous) per treatment strategy
| Antithrombotic treatment . | Recurrent events . | Relative risk (95% CI); I2 . | |
|---|---|---|---|
| n/N . | % . | ||
| Antiplatelet therapy only | 36/118 | 30.5 | |
| Antiplatelet + cytoreduction | 84/452 | 18.6 | 0.27 (0.07-1.04); 80.9% |
| Oral anticoagulation (any) | 42/120 | 35.0 | |
| Oral anticoagulation (any) + cytoreduction | 60/376 | 16.0 | 0.42 (0.19-0.92); 62.7% |
| Oral anticoagulation + antiplatelet therapy | 4/16 | 25.0 | |
| Oral anticoagulation + antiplatelet + cytoreduction | 9/37 | 24.3 | 0.60 (0.18-2.01); 36.3% |
| No antithrombotic treatment or cytoreduction | 12/33 | 36.4 | |
| Cytoreduction only | 31/101 | 30.7 | 0.50 (0.37-0.67); 0.0% |
| Recurrent thrombosis per type of oral anticoagulant | |||
| VKA only | 39/106 | 36.8 | |
| VKA + cytoreduction | 55/313 | 17.6 | 0.51 (0.23-1.14); 62.2% |
| DOAC only | 3/14 | 21.4 | |
| DOAC + cytoreduction | 5/63 | 7.9 | 0.21 (0.08-0.60); 16.9% |
| VKA + antiplatelet therapy | 4/11 | 36.4 | |
| VKA + antiplatelet + cytoreduction | 9/37 | 24.3 | 0.43 (0.16-1.15); 0% |
| DOAC + antiplatelet therapy | 0/5 | 0% | — |
| Antithrombotic treatment . | Recurrent events . | Relative risk (95% CI); I2 . | |
|---|---|---|---|
| n/N . | % . | ||
| Antiplatelet therapy only | 36/118 | 30.5 | |
| Antiplatelet + cytoreduction | 84/452 | 18.6 | 0.27 (0.07-1.04); 80.9% |
| Oral anticoagulation (any) | 42/120 | 35.0 | |
| Oral anticoagulation (any) + cytoreduction | 60/376 | 16.0 | 0.42 (0.19-0.92); 62.7% |
| Oral anticoagulation + antiplatelet therapy | 4/16 | 25.0 | |
| Oral anticoagulation + antiplatelet + cytoreduction | 9/37 | 24.3 | 0.60 (0.18-2.01); 36.3% |
| No antithrombotic treatment or cytoreduction | 12/33 | 36.4 | |
| Cytoreduction only | 31/101 | 30.7 | 0.50 (0.37-0.67); 0.0% |
| Recurrent thrombosis per type of oral anticoagulant | |||
| VKA only | 39/106 | 36.8 | |
| VKA + cytoreduction | 55/313 | 17.6 | 0.51 (0.23-1.14); 62.2% |
| DOAC only | 3/14 | 21.4 | |
| DOAC + cytoreduction | 5/63 | 7.9 | 0.21 (0.08-0.60); 16.9% |
| VKA + antiplatelet therapy | 4/11 | 36.4 | |
| VKA + antiplatelet + cytoreduction | 9/37 | 24.3 | 0.43 (0.16-1.15); 0% |
| DOAC + antiplatelet therapy | 0/5 | 0% | — |